Pharmacological activity of PGI2 and its metabolite 6-OXO-PGF1α on human uterus and fallopian tubes
- 1 June 1978
- journal article
- research article
- Published by Elsevier in Prostaglandins
- Vol. 15 (6), 1045-1054
- https://doi.org/10.1016/0090-6980(78)90047-3
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- The effects of prostacyclin (PGI2) on tissues which detect prostaglandins (PG'S)Prostaglandins, 1977
- Inhibition of platelet aggregation by a placental substance with prostacyclin-like activityNature, 1977
- Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heartNature, 1977
- Effects of prostacyclin (PGX) on cyclic AMP concentrations in human plateletsProstaglandins, 1977
- PRODUCTION OF PROSTAGLANDINS BY THE PSEUDOPREGNANT RAT UTERUS, in vitro, AND THE EFFECT OF TAMOXIFEN WITH THE IDENTIFICATION OF 6‐KETO‐PROSTAGLANDIN F1α AS A MAJOR PRODUCTBritish Journal of Pharmacology, 1977
- HUMAN ARTERIAL AND VENOUS TISSUES GENERATE PROSTACYCLIN (PROSTAGLANDIN X), A POTENT INHIBITOR OF PLATELET AGGREGATIONThe Lancet, 1977
- Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregationProstaglandins, 1976
- Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxidesProstaglandins, 1976
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976
- Prostaglandins released by the SpleenNature, 1968